As ADCs as a modality see continued clinical progress, drug developers are becoming more creative with their drug design and new analytical technologies are improving the resolution so that you can understand the characteristics of your drug. However, key regulatory questions are arising and agency expectations regarding what needs to be characterized and to what degree, what quality attributes are critical, and what variation is allowed in control processes are at the forefront of mind.

The 2nd ADC Analytical Development Summit is your only and definitive event dedicated to giving you full coverage of the core analytical challenges facing ADC developers including drug-linker, drug substance, drug formulation and drug product to enable you to understand your drug in more depth and confidently enter conversations with regulators to achieve regulatory approval.

With an increased focus on ADC comparability, connect with 100+ likeminded experts from leading companies including Merck & Co., GlaxoSmithKline, Mersana Therapeutics and more to take a deep dive into the issues surrounding the analytical field such as the complexity of the ADC, bioassays and regulatory requirements, to name a few.